Author

Bruce E. Sands

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Bruce E. Sands  et al.

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB
EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

Bruce E. Sands  et al.

ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Bruce E. Sands  et al.

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY
ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Bruce E. Sands  et al.

INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY
INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY

Bruce E. Sands  et al.

IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Bruce E. Sands  et al.

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Bruce E. Sands  et al.

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Bruce E. Sands  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Bruce E. Sands  et al.

Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)
Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)

Bruce E. Sands  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Bruce E. Sands  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

Bruce E. Sands  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY

Bruce E. Sands  et al.

GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Bruce E. Sands  et al.

EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Bruce E. Sands  et al.

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Bruce E. Sands  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Bruce E. Sands  et al.

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Bruce E. Sands  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Bruce E. Sands  et al.

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Bruce E. Sands  et al.

Item 21 - 40 / 73
1
2
3 4